Baker's yeast as a tool for the development of antifungal drugs which target cell integrity - an update

被引:13
作者
Heinisch, Juergen J. [1 ]
机构
[1] Univ Osnabruck, Fachbereich Biol Chem, AG Genetik, D-49076 Osnabruck, Germany
关键词
bioinformatics; cell wall integrity pathway; genetic screens; plasma membrane;
D O I
10.1517/17460441.3.8.931
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The yeast Saccharomyces cerevisiae has developed into a general eukaryotic model system because of the widespread use of genetic manipulation and the availability of whole genome approaches. it can serve as a reference for gene and protein functions in pathogenic fungi. Moreover, high-throughput drug screens developed in baker's yeast are slowly being adapted to these fungi. This is of particular interest in the light of increasing numbers of fungal human and plant diseases. Objective: This review summarizes briefly the variety of new approaches for drug development and explains resistance mechanisms that are based on modern yeast genetics. Methods: Concentrating on the cell envelope, the principles underlying different screens are explained and examples for drugs under investigation and already in use are given. Conclusion: In recent years the potency of yeast genetics for drug development has been extended in an unprecedented scale. Nevertheless, the constant advent in this field, in combination with bioinformatic approaches, indicates that today we can only see the tip of the iceberg of the discoveries to be made.
引用
收藏
页码:931 / 943
页数:13
相关论文
共 83 条
[1]   The mode of antifungal action of plant, insect and human defensins [J].
Aerts, A. M. ;
Francois, I. E. J. A. ;
Cammue, B. P. A. ;
Thevissen, K. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2008, 65 (13) :2069-2079
[2]  
Anderson JB, 2003, GENETICS, V163, P1287
[3]   FKBP12 controls aspartate pathway flux in Saccharomyces cerevisiae to prevent toxic intermediate accumulation [J].
Arévalo-Rodríguez, M ;
Pan, XW ;
Boeke, JD ;
Heitman, J .
EUKARYOTIC CELL, 2004, 3 (05) :1287-1296
[4]   Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action [J].
Baetz, K ;
McHardy, L ;
Gable, K ;
Tarling, T ;
Rebérioux, D ;
Bryan, J ;
Andersen, RJ ;
Dunn, T ;
Hieter, P ;
Roberge, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (13) :4525-4530
[5]   Antifungal chemical compounds identified using a C-elegans pathogenicity assay [J].
Breger, Julia ;
Fuchs, Beth Burgwyn ;
Aperis, George ;
Moy, Terence I. ;
Ausubel, Frederick M. ;
Mylonakis, Eleftherios .
PLOS PATHOGENS, 2007, 3 (02) :168-178
[6]   Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? [J].
Brogden, KA .
NATURE REVIEWS MICROBIOLOGY, 2005, 3 (03) :238-250
[7]   Why yeast cells can undergo apoptosis:: death in times of peace, love, and war [J].
Buettner, Sabrina ;
Eisenberg, Tobias ;
Herker, Eva ;
Carmona-Gutierrez, Didac ;
Kraemer, Guido ;
Madeo, Frank .
JOURNAL OF CELL BIOLOGY, 2006, 175 (04) :521-525
[8]   Utilization of target-specific, hypersensitive strains of Saccharomyces cerevisiae to determine the mode of action of antifungal compounds [J].
Buurman, ET ;
Andrews, B ;
Blodgett, AE ;
Chavda, JS ;
Schnell, NF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2558-2560
[9]   Consistent patterns of rate asymmetry and gene loss indicate widespread neofunctionalization of yeast genes after whole-genome duplication [J].
Byrne, Kevin P. ;
Wolfe, Kenneth H. .
GENETICS, 2007, 175 (03) :1341-1350
[10]  
Cruz MC, 1999, MOL CELL BIOL, V19, P4101